Advertisement

Topics

EMA and FDA aim to slash Gaucher disease R&D costs

05:43 EDT 5 Jul 2017 | pharmaphorum

US and European regulators want to promote the development of drugs for paediatric Gaucher disease, moves which could also apply to other rare diseases in children. The collaborative approach aims to make drug development in Gaucher disease (a...

Original Article: EMA and FDA aim to slash Gaucher disease R&D costs

NEXT ARTICLE

More From BioPortfolio on "EMA and FDA aim to slash Gaucher disease R&D costs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...